Sarah Boyce is the President and CEO of Avidity Biosciences, a pioneering biopharmaceutical company. With over 25 years of global leadership experience in the pharmaceutical and biopharmaceutical industries, she has been instrumental in transforming Avidity from a research-focused entity into a clinical-stage company. Under her leadership, the company has advanced multiple therapies into clinical development and expanded its proprietary RNA technology.
Who is the CEO of Avidity Biosciences?
With a robust background in the pharmaceutical and biopharmaceutical industries, Sarah Boyce has been at the helm of Avidity Biosciences since October 2019. Her leadership has been pivotal in transitioning the company from a research-focused entity to a clinical-stage biopharmaceutical firm. Boyce's extensive experience includes executive roles at notable companies such as Akcea Therapeutics, Ionis Pharmaceuticals, and Novartis Oncology.
She has successfully led Avidity through significant milestones, including a Series C funding round and an IPO, while advancing multiple therapies into clinical development. Her vision continues to drive the company's innovative approach to RNA therapeutics.
Work History
Sarah Boyce's extensive career in the pharmaceutical and biopharmaceutical industries includes a variety of leadership roles at several notable companies. Her work history is as follows:
Education History
Sarah Boyce's educational journey began at The University of Manchester, where she laid the foundation for her illustrious career in the pharmaceutical and biopharmaceutical industries. Although specific details about her degree or field of study are not provided, her time at this prestigious institution undoubtedly equipped her with the knowledge and skills that have been instrumental in her professional success. The University of Manchester, known for its strong emphasis on research and innovation, likely played a significant role in shaping Boyce's approach to leadership and scientific advancement.
When did Sarah Boyce join Avidity Biosciences?
Since joining Avidity Biosciences in October 2019, Sarah Boyce has served as the President and CEO, bringing her extensive experience in the pharmaceutical and biopharmaceutical industries to the forefront of the company's operations. Her tenure at Avidity has spanned approximately five years, during which she has been instrumental in advancing the company's innovative RNA therapeutics. Boyce's leadership has been pivotal in transitioning Avidity from a research-focused entity to a clinical-stage biopharmaceutical firm, driving significant milestones and fostering a culture of scientific excellence.